News

OncoTherics and UHN sign MoU. Left to right ar Bharti Ranawaya (BDM, UHN), Mark Taylor (Director of Commercialisation, UHN), Stefan Ogrodzinski (CEO OncoTherics), John Reid (Director TD&C, UHN) and Laurence Patterson (Chair, SAB OncoTherics).

OncoTherics and UHN sign MoU. Left to right ar Bharti Ranawaya (BDM, UHN), Mark Taylor (Director of Commercialisation, UHN), Stefan Ogrodzinski (CEO OncoTherics), John Reid (Director TD&C, UHN) and Laurence Patterson (Chair, SAB OncoTherics).

OncoTherics signs MoU with University Health Network (UHN), Toronto

Author: Stefan Ogrodzinski

OncoTherics and University Health Network (UHN), Toronto have signed a memorandum of understanding to progress the development of the company’s novel hypoxia-activated cancer drugs at the Princess Margaret Cancer Centre (PMCC) – a world class facility for the detection of tumour hypoxia and the treatment of pancreatic cancer.

Stefan Ogrodzinski (CEO, OncoTherics) said “This is an exciting development for OncoTherics. There is an excellent alignment of interests between the company’s novel hypoxia activated prodrug technology and PMCC’s expertise in the detection of tumour hypoxia.”